1 |
|
|
Main adverse reactions motivating the substitution of Dolutegravir in Antiretroviral Therapy regimens in Brazil |
31.07.2018 - 10:39 |
|
2 |
|
|
How it was possible to offer Integrase Inhibitor as first line ART while maintaining the sustainability of the Brazilian policy of universal access to drugs |
31.07.2018 - 10:36 |
|
3 |
|
|
Virological monitoring of the switch from RAL-containing to DTG-containing regimens in Brazil: data from a real-world cohort |
31.07.2018 - 10:37 |
|
4 |
|
|
User profiles, regimen choices and types of exposure in HIV post-exposure prophylaxis before and after after the implementation of guidelines in Brazil |
26.07.2018 - 17:53 |
|
5 |
|
|
Factors associated with adherence to antiretroviral therapy in Brazil in 2017 |
26.07.2018 - 17:53 |
|
6 |
|
|
Clinical monitoring system for people living with HIV (SIMC) and continuum care improvement in Brazilian Brazil |
26.07.2018 - 17:53 |
|
7 |
|
|
Brazilian e-health strategy for expanding, strengthening and monitoring ART adherence |
26.07.2018 - 17:53 |
|